AstraZeneca Statistics

Total Valuation

AstraZeneca has a market cap or net worth of EUR 185.57 billion. The enterprise value is 209.50 billion.

Market Cap	185.57B
Enterprise Value	209.50B

Important Dates

The next estimated earnings date is Tuesday, July 29, 2025.

Earnings Date	Jul 29, 2025
Ex-Dividend Date	Feb 20, 2025

Share Statistics

Current Share Class	1.55B
Shares Outstanding	n/a
Shares Change (YoY)	+0.08%
Shares Change (QoQ)	-0.06%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	1.54B

Valuation Ratios

The trailing PE ratio is 25.81 and the forward PE ratio is 15.04.

PE Ratio	25.81
Forward PE	15.04
PS Ratio	3.65
PB Ratio	4.88
P/TBV Ratio	n/a
P/FCF Ratio	17.99
P/OCF Ratio	15.32
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 12.43, with an EV/FCF ratio of 20.30.

EV / Earnings	29.13
EV / Sales	4.21
EV / EBITDA	12.43
EV / EBIT	17.02
EV / FCF	20.30

Financial Position

The company has a current ratio of 0.90, with a Debt / Equity ratio of 0.77.

Current Ratio	0.90
Quick Ratio	0.69
Debt / Equity	0.77
Debt / EBITDA	1.70
Debt / FCF	2.84
Interest Coverage	10.16

Financial Efficiency

Return on equity (ROE) is 19.79% and return on invested capital (ROIC) is 11.73%.

Return on Equity (ROE)	19.79%
Return on Assets (ROA)	8.16%
Return on Invested Capital (ROIC)	11.73%
Return on Capital Employed (ROCE)	17.65%
Revenue Per Employee	539,442
Profits Per Employee	76,253
Employee Count	94,300
Asset Turnover	0.53
Inventory Turnover	1.72

Taxes

In the past 12 months, AstraZeneca has paid 1.40 billion in taxes.

Income Tax	1.40B
Effective Tax Rate	16.26%

Stock Price Statistics

The stock price has decreased by -19.13% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-19.13%
50-Day Moving Average	124.07
200-Day Moving Average	131.55
Relative Strength Index (RSI)	34.89
Average Volume (20 Days)	11,822

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, AstraZeneca had revenue of EUR 50.87 billion and earned 7.19 billion in profits. Earnings per share was 4.60.

Revenue	50.87B
Gross Profit	41.94B
Operating Income	12.59B
Pretax Income	8.60B
Net Income	7.19B
EBITDA	16.91B
EBIT	12.59B
Earnings Per Share (EPS)	4.60

Full Income Statement

Balance Sheet

The company has 4.99 billion in cash and 29.34 billion in debt, giving a net cash position of -24.35 billion.

Cash & Cash Equivalents	4.99B
Total Debt	29.34B
Net Cash	-24.35B
Net Cash Per Share	n/a
Equity (Book Value)	38.05B
Book Value Per Share	24.50
Working Capital	-2.77B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 12.11 billion and capital expenditures -1.79 billion, giving a free cash flow of 10.32 billion.

Operating Cash Flow	12.11B
Capital Expenditures	-1.79B
Free Cash Flow	10.32B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 82.44%, with operating and profit margins of 24.75% and 14.14%.

Gross Margin	82.44%
Operating Margin	24.75%
Pretax Margin	16.90%
Profit Margin	14.14%
EBITDA Margin	33.24%
EBIT Margin	24.75%
FCF Margin	20.28%

Dividends & Yields

This stock pays an annual dividend of 2.93, which amounts to a dividend yield of 2.44%.

Dividend Per Share	2.93
Dividend Yield	2.44%
Dividend Growth (YoY)	10.55%
Years of Dividend Growth	3
Payout Ratio	63.60%
Buyback Yield	-0.08%
Shareholder Yield	2.36%
Earnings Yield	3.87%
FCF Yield	5.56%

Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

AstraZeneca has an Altman Z-Score of 3.08 and a Piotroski F-Score of 7.

Altman Z-Score	3.08
Piotroski F-Score	7